Functional factor VIII made with von Willebrand factor at high levels in transgenic milk

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 11, 2011, Pages 2235-2242

  Pipe, S W ^a   Miao, H ^a   Butler, S P ^b   Calcaterra, J ^c   Velander, W H ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Factor VIII; Hemophilia; Mammary gland; Modified B domain; Recombinant protein; Transgenic animal; Von Willebrand factor

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBOPLASTIN; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ARTICLE; BIOENGINEERING; BLOOD CLOTTING; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA A; IMMUNOAFFINITY CHROMATOGRAPHY; IN VIVO STUDY; MAMMARY GLAND; MILK; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; TRANSGENIC MILK; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; GENETICS; HUMAN; METABOLISM;

ANIMALS; BIOENGINEERING; CELLS, CULTURED; FACTOR VIII; HEMOPHILIA A; HUMANS; MICE; MICE, TRANSGENIC; MILK; VON WILLEBRAND FACTOR;

EID: 80055102461     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04505.x     Document Type: Article

References (40)

1. Kasper CK, Mannucci PM, Bulyzhenkov V, Brettler DB, Chuansumrit A, Heijnen L, Isarankura P, Kernoff PB, Peake I, Rickard KA, Schulman S, Smit Sibinga CT. Haemophilia in the 1990s: report of a joint meeting of the World Health Organization and World Federation of Hemophilia. Vox Sang 1991; 61: 221-4.
2. Rosendaal FR, Briet E. The increasing prevalence of haemophilia. Thromb Haemost 1990; 63: 145.
3. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
4. Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham EGD, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA clones. Nature (London) 1984; 312: 330-7.
5. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature (London) 1984; 312: 337-42.
6. Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihemophilic factor. Nature (London) 1984; 312: 342-7.
7. Jankowski MA, Patel H, Rouse JC, Marzilli LA, Weston SB, Sharpe PJ. Defining 'full-length' recombinant factor VIII: a comparative structural analysis. Haemophilia 2007; 13: 30-7.
8. Pipe SW, High KA, Ohashi K, Ural AU, Lillicrap D. Progress in the molecular biology of inherited bleeding disorders. Haemophilia 2008; 14(Suppl. 3): 130-7.
9. Pipe SW, Saint-Remy J-M, Walsh CE. New high-technology products for the treatment of haemophilia. Haemophilia 2004; 10: 55-63.
10. Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259-72.
11. Koeberl DD, Halbert CL, Krumm A, Miller AD. Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum Gene Ther 1995; 6: 469-79.
12. Hoeben RC, Fallaux FJ, Cramer SJ, van den Wollenberg DJM, van Ormondt H, Brieet E, van der Eb AJ. Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995; 85: 2447-54.
13. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-62.
14. Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103: 3412-19.
15. Pittman DD, Millenson M, Marquette K, Bauer K, Kaufman RJ. A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage. Blood 1992; 79: 389-97.
16. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 1989; 9: 1233-42.
17. Chen C-M, Wang C-H, Wu S-C, Lin C-C, Lin S-H, Cheng WTK. Temporal and spatial expression of biologically active human factor VIII in the milk of transgenic mice driven by mammary-specific bovine lactalbumin regulation sequences. Transgenic Res 2002; 11: 257-68.
18. Chrenek P, Vasicek D, Makarevich AV, Jurcik R, Suvegova K, Parkanyi V, Bauer M, Rafay J, Batorova A, Paleyanda RK. Increased transgene integration efficiency upon microinjection of DNA into both pronuclei of rabbit embryos. Transgenic Res 2005; 14: 417-28.
19. Cherenek P, Ryban L, Vetr H, Makarevich AV, Uhrin P, Paleyanda RK, Binder BR. Expression of recombinant human factor viii in milk of several generations of transgenic rabbits. Transgenic Res 2007; 16: 353-61.
20. Niemann H, Halter R, Carnwath JW, Hermann D, Lemme E, Paul D. Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep. Transgenic Res 1999; 8: 237-47.
21. Paleyanda RK, Velander WH, Lee TK, Scandella DH, Gwazdauskas FC, Knight JW, Drohan WN, Lubon H. Transgenic pig produce functional human factor VIII in milk. Nat Biotechnol 1997; 15: 971-5.
22. Chauhan MS, Nadir S, Bailey TL, Pryor AW, Butler SP, Notter DR, Velander WH, Gwazdauskas FC. Bovine follicular dynamics, oocyte recovery, and development of oocytes microinjected with a green fluorescent protein construct. J Dairy Sci 1999; 82: 918-26.
23. Archibald AL, McClenaghan M, Hornsey V, Simons JP, Clark AJ. High-level expression of biologically active human alpha 1-antitrypsin in the milk of transgenic mice. Proc Natl Acad Sci USA 1990; 87: 5178-82.
24. Velander WH, Page RL, Morcol T, Russell CG, Canseco R, Young JM, Drohan WN, Gwazdauskas FC, Wilkins TD, Johnson JL. Production of biologically active human protein C in the milk of transgenic mice. Ann N Y Acad Sci 1992; 665: 391-403.
25. Michnick DA, Pittman DD, Wise RJ, Kaufman RJ. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 1994; 269: 20095-102.
26. Lollar P, Fay PJ, Fass DN. Factor VIII and factor VIIIa. Methods Enzymol 1993; 222: 128-43.
27. Jacquemin MG, Desqueper BG, Benhida A, Vander Elst L, Hoylaerts MF, Bakkus M, Thielemans K, Arnout J, Peerlinck K, Gilles JGG, Vermylen J, Saint-Remy J-MR. Mechanism and kinetics of factor viii inactivation: study with an igg4 monoclonal antibody derived from a hemophilia a patient with inhibitor. Blood 1998; 92: 496-506.
28. Bi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL, Bedian V, Kazazian HH Jr. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-50.
29. Clark AJ, Cowper A, Wallac R, Wright G, Simons JP. Rescuing transgene expression by co-integration. J Biotechnol 1992; 10: 1450-4.
30. Yull F, Binas B, Harold G, Wallace R, Clark AJ. Transgene rescue in the mammary gland is associated with transcription but does not require translation of BLG transgenes. Transgenic Res 1997; 6: 11-17.
31. Alpan O, Velander WH, van Cott KE, Butler SP, High KA, Sabatino D. Overcoming the immunological barriers to curing haemophilia. In: Studies TSIfB, ed. 6th Gene Therapy Workshop. La Jolla, CA: The Salk Institute for Biological Studies, 2002: 3885-91.
32. Mannucci PM, Bonomi AB. The future of hemophilia treatment. Haematologica/J Hematol 2004; 89: 774-6.
33. Korycka-Dahl M, Dumas BR, Chene N, Martal J. Plasmin activity in milk. J Dairy Sci 1983; 66: 704-11.
34. Clark AJ, Bessos H, Bishop JO, Brown P, Lathe HR, McClenaghan M, Prowse C, Simons JP, Whitelaw CBA, Wilmut I. Expression of human anti-hemophilic factor mix in the milk of transgenic sheep. J Biotechnol 1989; 7: 487-92.
35. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60: 390-404.
36. Leyte A, van Schijndel HB, Niehrs C, Huttner WB, Verbeet MP, Mertens K, van Mourik JA. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991; 266: 740-6.
37. Platokouki H, Pergantou H, Komitopoulou A, Xafaki P. First attempt at immune tolerance induction with factor VIII/von Willebrand factor concentrates in hemophilia A children with high-titer inhibitors. J Coagulation Disord 2010; 2: 35-40.
38. Echelard Y, Ziomek CA, Meade HM. Production of recombinant therapeutic proteins in the milk of transgenic animals. BioPharm Int. 2006; 19: 36-40, 2, 4, 6.
39. Gil GC, Velander WH, van Cott KE. Analysis of the N-glycans of recombinant human factor IX purified from transgenic pig milk. Glycobiology 2008; 18: 526-39.
40. Joziasse DH, Lee RT, Lee YC, Biessen EAL, Schiphorst WECM, Koeleman CAM, van den Eijnden DH. Alpha 3-galactosylated glycoproteins can bind to the hepatic asialoglycoprotein receptor. Eur J Biochem 2000; 267: 6501-8.